BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
Last trade$9.17
Day change-$0.22 (-2.34%)
Day range$8.95 – $9.70
Volume101,613
Market cap$378M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for BWAY.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for BWAY.
Recent news
Company coverage with links to the original publishers.
BrainsWay reported 34% year-over-year revenue growth to $18.1 million in Q3 2026, driven by 44% growth in Deep TMS system shipments (130 units) and expansion of its installed base beyond 2,000 systems. Insurance reimbursement coverage for SWIFT accelerated protocol reached 70 million covered lives, while gross margins improved to 78% from 75% year-over-year due to manufacturing scale efficiencies. The company is positioned for continued growth through enterprise partnerships and international expansion.
BrainsWay Ltd., a leader in non-invasive neurostimulation treatments, announced it will report third quarter 2026 financial results on November 10, 2026, with a conference call at 8:30 AM ET. The company will discuss operational highlights and provide a business update. BrainsWay's Deep TMS platform has three FDA-cleared indications for major depressive disorder, obsessive-compulsive disorder, and smoking addiction.
BrainsWay Ltd., a global leader in noninvasive brain stimulation technologies, announced it will report its second quarter 2026 financial results on August 12, 2026, followed by a conference call and webcast at 8:30 AM Eastern Time. The company will also provide operational highlights and business updates.
BrainsWay Ltd., a leader in noninvasive neurostimulation technologies, announced it will report first quarter 2026 financial results on May 13, 2026, with a conference call at 8:30 AM ET. The company highlighted growing U.S. payer support for nurse practitioner-administered TMS therapy and will participate in the Needham Virtual Healthcare Conference.
BrainsWay Ltd., a leader in noninvasive neurostimulation technologies, announced it will report fourth quarter and full year 2025 financial results on March 11, 2026, with a conference call at 8:30 AM ET. The company will discuss results and provide operational updates.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.